Search by Abstract Number Results

Abstract Number: 1442 • ACR Convergence 2024
Relationship Between Degenerative Lesions over Time in Axial Spondyloarthritis: 10-year Follow-up of the DESIR Cohort
Laura Pina Vegas¹, Floris van Gaalen², Miranda van Lunteren³, Damien Loeuille⁴, Caroline Morizot⁵, Esther Newsum⁶, Pascal Claudepierre⁷, Alain SARAUX⁸, Antoine Feydy⁹, Monique Reijnierse¹, Desiree van der Heijde¹⁰ and Sofia Ramiro¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Zuid-Holland, Netherlands, ³Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁴Phd, Nancy Vandoeuvre, Lorraine, France, ⁵Nancy University hospital, Nancy, France, ⁶Nij Smellinghe, Drachten, Netherlands, ⁷CHU Henri Mondor, AP-HP/EpiDermE, UPEC, Créteil, France, ⁸CHU Brest, Brest, France, ⁹CHU Cochin, AP-HP, Paris, France, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Spinal degenerative lesions (DLs) are commonly seen/reported in radiographs and MRI in axSpA. However, the relationship between the different DLs over time has not…
Abstract Number: 1442 • ACR Convergence 2023
Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus
Renata Baronaite Hansen¹, Julia Simard², Mikkel Faurschou¹ and Søren Jacobsen³, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence…
Abstract Number: 1442 • ACR Convergence 2022
Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus
Anca Askanase¹, John Conklin², Michelle Petri³, Vasileios Kyttaris⁴, Yevgeniya Gartshteyn⁵, Wei Tang¹, Anja Kammesheidt⁶ and Roberta Alexander², ¹Columbia University Medical Center, New York, NY, ²Exagen, Inc., Vista, CA, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Columbia University Medical Center, Glen Rock, NJ, ⁶self, Laguna Beach, CA
Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
Abstract Number: 1442 • ACR Convergence 2021
Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
Manuel Pombo-Suarez¹, Carlos Sanchez-Piedra², Juan J Gomez-Reino³, Kim Lauper⁴, Nevsun Inanc⁵, Anja Strangfeld⁶, Doreen Huschek⁷, Karel Pavelka⁸, Eirik Kristianslund⁹, Tore Kvien¹⁰, Ziga Rotar¹¹, Dan Nordström¹², Denis Choquette¹³, Ori Elkayam¹⁴, Burkhard Leeb¹⁵, Maria José Santos¹⁶, Kimme Hyrich¹⁷, Lianne Kearsley-Fleet¹⁸, Catalin Codreanu¹⁹, Denis Monguin²⁰, Delphine Courvoisier²⁰ and Axel Finckh²¹, ¹Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁴Geneva University Hospitals, Geneve, Switzerland, ⁵Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ¹²Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ¹³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ¹⁴Tel Aviv Medical Center, Tel Aviv, Israel, ¹⁵Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, ¹⁶Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹⁹Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²⁰Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²¹University Hospital of Geneva, Geneve - Vesenaz, Switzerland
Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
Abstract Number: 1442 • ACR Convergence 2020
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma¹, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.Methods: Patients receiving long-term…
Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting
Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
MASAOMI YAMASAKI¹, ¹Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
Abstract Number: 1442 • 2018 ACR/ARHP Annual Meeting
Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis
Walter P. Maksymowych¹, Xiaohang Wang², Joel Paschke¹, Rana Dadashova¹, Edna Hutchings¹ and Liang Li², ¹CaRE Arthritis, Edmonton, AB, Canada, ²Chemistry, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. Recent advancements in metabolomic profiling include dansylation liquid…
Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting
Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain Cantagrel⁵, Bernard Combe², Maxime Dougados⁶, René-Marc Flipo⁷, Alain Saraux⁸, Thierry Schaeverbeke⁹, Jean Sibilia¹⁰, Martin Soubrier¹¹, Olivier Vittecoq^12,13, Gabriel Baron¹⁴, Elodie Perrodeau¹⁵, Philippe Ravaud¹⁴ and Xavier Mariette¹⁶, ¹CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸Rheumatology, Brest University Hospital, Brest, France, ⁹Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹²INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ¹³Rheumatology Department and INSERM U 905, CHU Rouen, Rouen, France, ¹⁴Hôpital Hôtel Dieu, Paris, France, ¹⁵Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…
Abstract Number: 1442 • 2016 ACR/ARHP Annual Meeting
Suppression of Acute Arthritis By N-Methyl-3,4-Dichloropropionaniline (N-MeDCPA), a Reversible Orai Calcium Channel Inhibitor
John Barnett¹, Lisa Robinson², Jonathan Soboloff³, Rosana Schafer⁴, Ida Holaskova⁵, Meenal Elliott¹, Michelle Witt², Raphael Hirsch⁶ and Harry Blair⁷, ¹Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV, ²Pathology, West Virginia University, Morgantown, WV, ³Dept of Medical Genetics and Molecular Biochemistry, Temple University, Philadelphia, PA, ⁴Dept Micro, Immun & Cell Biol, West Virginia University, Morgantown, WV, ⁵West Virginia University, Morgantown, WV, ⁶Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, ⁷pathology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Bone maintenance is a balance between the removal of old bone by osteoclasts (OCL) and the production of new bone by osteoblasts. In the…
Abstract Number: 1442 • 2015 ACR/ARHP Annual Meeting
Descriptive Characteristics of Patients Prescribed Opioids for the Treatment of Chronic Pain
Jenna Goesling¹, Stephanie Moser², Afton L. Hassett³, Chad Brummett¹ and Natalie Gulau¹, ¹Anesthesiology, University of Michigan, Ann Arbor, MI, ²Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ³Anesthesiology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Opioids remain the cornerstone of acute pain therapy. However, there is little empirical evidence supporting the use of long-term opioid therapy for chronic pain.…
Abstract Number: 1442 • 2014 ACR/ARHP Annual Meeting
The 2013 ACC/AHA Cardiovascular Risk Prediction Model and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis
Vivian K. Kawai¹, Cecilia P. Chung², Joseph F. Solus¹, Annette Oeser¹, Paolo Raggi³ and C. Michael Stein¹, ¹Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³University of Alberta, Edmonton, AB, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk of atherosclerotic cardiovascular (CV) disease that is underestimated by the Framingham risk score (FRS). We hypothesized…
Abstract Number: 1442 • 2013 ACR/ARHP Annual Meeting
Three-Year Drug Survival and Effectiveness Of Abatacept and Tocilizumab In Patients with Rheumatoid Arthritis Treated In Routine Care. Results From The Nationwide Danish Danbio Registry
HCB Leffers^1,2, Mikkel Østergaard³, Bente Glintborg⁴, Niels Steen Krogh⁵, Ulrik Tarp⁶, Tove Lorenzen⁷, Annette Hansen⁸, Lene Dreyer⁹ and Merete L. Hetland³, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frderiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark
Background/Purpose: Treatment with abatacept and tocilizumab has been shown to be efficacious in rheumatoid arthritis (RA) patients refractory to tumor necrosis factor inhibitor (TNFi). However,…
Abstract Number: 1442 • 2012 ACR/ARHP Annual Meeting
IRF-1 Deficient Lupus-Prone MRL/Lpr Mice Show Reduced Glomerulonephritis but Develop Severe Interstitial Nephritis, Renal Vasculitis and Pulmonary Granulomas with Propensity for Th2 Polarity
Hidemaru Sekine¹, Takeshi Machida¹, Natsumi Sakamoto¹, Eiji Suzuki², Xian Zhang³, Christopher Reilly⁴ and Gary S. Gilkeson⁵, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, ⁴Virginia Tech, Blacksburg, VA, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: The transcription factor interferon regulatory factor-4 (IRF-4) and -1 (IRF-1) are members of the IRF family of transcription regulators and involved in the development…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].